Research Publications on Herceptin Assays



This page is designed to facilitate user to provide summary of data from different studies. For example from each paper we got information how may assay were performed.

For more info Guide/Help




Reset Search:
Serial No. Title and Link of Article Assays Cell lines Supplementary Drug Changes in cell lines PMIDs PDF of Article
1 Insulin-like growth factor-I receptor signaling and resistance to trastuzumab48215511752009
2 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate 1211212586780
3 HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma)612412912973
4 Rational combinations of trastuzumab with chemotherapeutic drugs used in the55410115150302
5 P27(kip1) down-regulation is associated with trastuzumab resistance in breast30111215173011
6 Human epidermal growth factor receptor 2 status modulates subcellular1112215173068
7 PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN 1323315324695
8 Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast 632115830342
9 Insulin-like growth factor-I receptor/human epidermal growth factor receptor 23613716322262
10 Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the421116384610
11 Activity of the dual kinase inhibitor lapatinib (GW572016) against1642716452222
12 PC cell-derived growth factor stimulates proliferation and confers Trastuzumab1021316857791
13 A collection of breast cancer cell lines for the study of functionally distinct11111117157791
14 ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.85161117525746
15 Heregulin beta1 drives gefitinib-resistant growth and invasion in312217686159
16 Preclinical testing of clinically applicable strategies for overcoming4617317908983
17 Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast 1222218316611
18 Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.3321818579663
19 Transforming growth factor beta engages TACE and ErbB3 to activate1014818625725
20 Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on3032218641009
21 Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER21212318645000
22 Trastuzumab-resistant breast cancer cells remain sensitive to the auger1822118703606
23 Improvement of sensitivity to tamoxifen in estrogen receptor-positive and1212118768663
24 A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and2572318769124
25 Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility811218834540
26 Modeling ERBB receptor-regulated G1/S transition to find novel targets for de6643119118495
27 Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast3926819190349
28 Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.2871119276389
29 Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer1611519301121
30 t10c12 conjugated linoleic acid suppresses HER2 protein and enhances apoptosis in412219399184
31 MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer5933819415485
32 Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations1612119509167
33 Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a212219509242
34 Association between gain-of-function mutations in PIK3CA and resistance to73173719633047
35 In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive4613619636556
36 HER2 signaling pathway activation and response of breast cancer cells to4846819701706
37 Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and 913319855434
38 PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits1831119874578
39 Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human 4033519887601
40 Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab32102720028874
41 Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like3221620103628
42 Sodium nitroprusside infusion does not dilate cerebral resistance vessels during 31222021198
43 FoxM1 mediates resistance to herceptin and paclitaxel.94382320530690
44 FOXO1A is a target for HER2-overexpressing breast tumors.59323320551062
45 Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive3222620647220
46 Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast2012420844753
47 Recombinant human erythropoietin antagonizes trastuzumab treatment of breast2132521075308
48 Carbamazepine promotes Her-2 protein degradation in breast cancer cells by615421082217
49 HER2 phosphorylation is maintained by a PKB negative feedback loop in response to3217621203579
50 Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in39121521321214